Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1261473
Disease: Sarcoma
Sarcoma 		0.310 GenomicAlterations group CGI
CUI: C0029607
Disease: Other emphysema
Other emphysema 		0.200 Biomarker phenotype MGD
CUI: C1608408
Disease: Malignant transformation
Malignant transformation 		0.050 AlteredExpression phenotype BEFREE The proto-oncogene C-jun acts as a transcriptional activator or repressor for numerous cellular genes, and the overexpression of these genes may cause malignant transformation. 1404666 1992
CUI: C0007134
Disease: Renal Cell Carcinoma
Renal Cell Carcinoma 		0.020 AlteredExpression disease BEFREE We investigated the expression of jun genes in renal cell cancer (RCC) and their regulation by cytokines and transforming growth factor beta 1 (TGF-b1). 1404666 1992
CUI: C0023470
Disease: Myeloid Leukemia
Myeloid Leukemia 		0.030 AlteredExpression disease BEFREE The present work demonstrates that treatment of human myeloid leukemia cells (HL-60, U-937, and KG-1) with CDDP is associated with increased expression of the c-jun gene and that this effect is related to activation by a transcriptional mechanism. 1737349 1992
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE It recently has been reported that certain nuclear receptors can antagonize the tumor promoter 12-O-tetradeconylphorbol-13-acetate (TPA) by direct interaction with the transcription factor AP-1, and that the AP-1 constituents cJun and cFos can inhibit receptor activity. 1791843 1991
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia 		0.020 AlteredExpression disease BEFREE Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia. 2113601 1990
CUI: C0024198
Disease: Lyme Disease
Lyme Disease 		0.020 Biomarker disease BEFREE Ninety-four serum specimens from patients having Lyme borreliosis were tested for reactivity with P39. 2380361 1990
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.050 Biomarker disease BEFREE Finally, this study identified a breakpoint at 1p32 that was localized between the genes JUN and MYCL for one neuroblastoma thus establishing the order of these genes as centromere, JUN, MYCL, telomere. 2776489 1989
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.050 Biomarker disease BEFREE Finally, this study identified a breakpoint at 1p32 that was localized between the genes JUN and MYCL for one neuroblastoma thus establishing the order of these genes as centromere, JUN, MYCL, telomere. 2776489 1989
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.050 Biomarker disease BEFREE Finally, this study identified a breakpoint at 1p32 that was localized between the genes JUN and MYCL for one neuroblastoma thus establishing the order of these genes as centromere, JUN, MYCL, telomere. 2776489 1989
CUI: C3854222
Disease: Human immunodeficiency virus (HIV) II infection category B1
Human immunodeficiency virus (HIV) II infection category B1 		0.040 Biomarker disease BEFREE Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. 7474072 1995
CUI: C0004096
Disease: Asthma
Asthma 		0.060 Biomarker disease BEFREE To study this reduced DNA binding, we examined the ability of the nuclear translocated transcription factors activator protein 1 (AP-1), nuclear factor kappa B (NF-kappa B) and cyclic AMP response element-binding protein (CREB) to bind to their DNA-binding sites and to interact with GR in PBMC from patients with steroid-sensitive and steroid-resistant asthma. 7500041 1995
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 AlteredExpression phenotype BEFREE Jun proteins can thus be key intermediates in regulatory cascades which result in the differential modulation of the AFP and albumin gene expression in the course of liver development and carcinogenesis. 7537266 1995
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm 		0.020 AlteredExpression disease BEFREE We evaluated the effects of recombinant human G-CSF, rhGM-CSF, rhM-CSF and rhIL-1 alpha on proliferation and regulation of c-jun gene expression in 4 human ovarian-carcinoma (HOC) cell lines, NIH:OVCAR-3, SK-OV-3, HEY and BG-1, and in one primary ovarian tumor in vitro. 7591243 1995
CUI: C0023418
Disease: leukemia
leukemia 		0.010 AlteredExpression disease BEFREE In this work, we demonstrate that the levels of c-jun mRNA, c-Jun protein, and DNA binding activity of a nuclear transcription factor AP-1 to 12-o-tetradecanoylphorbol 13-acetate responsive elements all increased following treatment with the cell-permeable ceramide, N-acetylsphingosine in human leukemia HL-60 cells. 7592995 1995
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.010 AlteredExpression disease BEFREE In this work, we demonstrate that the levels of c-jun mRNA, c-Jun protein, and DNA binding activity of a nuclear transcription factor AP-1 to 12-o-tetradecanoylphorbol 13-acetate responsive elements all increased following treatment with the cell-permeable ceramide, N-acetylsphingosine in human leukemia HL-60 cells. 7592995 1995
CUI: C0004096
Disease: Asthma
Asthma 		0.060 Biomarker disease BEFREE Secondary steroid resistance in asthma may arise in response to the release of cytokines that activate AP-1 and other transcription factors that bind directly to GR. 7633872 1995
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE The c-fos and c-jun genes were also activated in these tumors. 7732661 1995
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Since P(+)-to-tumor phenotype progression occurred in cells overexpressing c-jun but not AP-1, we propose that P(+)-to-transformed phenotype progression is c-jun dependent and AP-1 independent. 7766308 1995
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.300 Biomarker disease CTD_human Differential expression of c-jun, c-fos and hsp 70 mRNAs after folic acid and ischemia-reperfusion injury: effect of antioxidant treatment. 7922267 1994
CUI: C0038220
Disease: Status Epilepticus
Status Epilepticus 		0.300 Biomarker disease CTD_human Distinctive rat brain immediate early gene responses to seizures induced by lithium plus pilocarpine. 7984056 1994
CUI: C0270823
Disease: Petit mal status
Petit mal status 		0.300 Biomarker disease CTD_human Distinctive rat brain immediate early gene responses to seizures induced by lithium plus pilocarpine. 7984056 1994
CUI: C0311335
Disease: Grand Mal Status Epilepticus
Grand Mal Status Epilepticus 		0.300 Biomarker disease CTD_human Distinctive rat brain immediate early gene responses to seizures induced by lithium plus pilocarpine. 7984056 1994
CUI: C0393734
Disease: Complex Partial Status Epilepticus
Complex Partial Status Epilepticus 		0.300 Biomarker disease CTD_human Distinctive rat brain immediate early gene responses to seizures induced by lithium plus pilocarpine. 7984056 1994